12 Best Performing Biotech Stocks in 2023
In this piece, we will take a look at the 12 best performing biotechnology stocks in 2023.
Minerva Neurosciences Inc. (NERV)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Vivo Capital Albert Cha And Frank Kung | 4,322,747 | $23,991,246 | 2.19% | |
| 2. | Balyasny Asset Management Dmitry Balyasny | 4,257,000 | $23,626,350 | -1% | 0.03% |
| 3. | Logos Capital Arsani William | 3,288,777 | $18,252,712 | +3% | 0.79% |
| 4. | Farallon Capital Thomas Steyer | 2,365,000 | $13,125,750 | 0.06% | |
| 5. | Spruce Street Capital Alex Rosen And Simon Basseyn | 1,655,500 | $9,188,025 | 1.8% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.97 | 7,000 | $20,790.00 | 20,333 | 2020-09-10 | Filing | |
| $5.50 | 3,500 | $19,250.00 | 26,111 | 2019-06-27 | Filing | |
| $5.37 | 10,000 | $53,700.00 | 13,333 | 2019-06-26 | Filing | |
| $5.25 | 1,000 | $5,250.00 | 1,000 | 2019-06-26 | Filing | |
| $5.60 | 10,000 | $56,000.00 | 10,000 | 2019-06-26 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.76 | 3,641 | $13,690.16 | 68,994 | 2023-05-02 | Filing | |
| $3.85 | 23,753 | $91,449.05 | 72,635 | 2023-05-01 | Filing | |
| $3.85 | 22,082 | $85,015.70 | 51,324 | 2023-05-01 | Filing | |
| $4.48 | 3,580 | $16,038.40 | 17,518 | 2023-05-01 | Filing | |
| $0.88 | 55,635 | $48,958.80 | 163,553 | 2021-12-01 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 977,069 | $3,274,364 | 0% | |
| 2. | 75,580 | $253,192 | 0% | |
| 3. | 42,250 | $138,158 | 0% | |
| 4. | 29,698 | $99,488 | 0% | |
| 5. | 14,519 | $48,639 | 0% |
News See All
Minerva Neurosciences, Inc. (NASDAQ:NERV) Q1 2023 Earnings Call Transcript
Minerva Neurosciences, Inc. (NASDAQ:NERV) Q1 2023 Earnings Call Transcript May 15, 2023 Minerva Neurosciences, Inc. beats earnings expectations. Reported EPS is $-1.31, expectations were $-1.63.
Minerva Neurosciences, Inc. (NASDAQ:NERV) Q4 2022 Earnings Call Transcript
Minerva Neurosciences, Inc. (NASDAQ:NERV) Q4 2022 Earnings Call Transcript March 8, 2023 Operator: Good day, and thank you for standing by.
10 Best Biotech Stocks Under $10
In this article, we will look at the 10 best biotech stocks under $10.
Hedge Funds Are Buying Minerva Neurosciences, Inc (NERV)
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not...
Minerva Neurosciences, Inc (NERV): Are Hedge Funds Right About This Stock?
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not...
Hedge Funds Aren't Crazy About Minerva Neurosciences Inc (NERV) Anymore
Reputable billionaire investors such as Nelson Peltz and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required...
Baker Bros. Opened Positions In These 5 Healthcare Stocks
Julian Baker and Felix Baker founded Baker Bros. Advisors in 2000.
Kingsway Financial Services Inc. (USA) (KFS) and Two Pharmaceutical Companies Register Insider Buying
The U.S. Securities and Exchange Commission prohibits executives and Board members from trading their company’s stock if they possess material non-public information about their company.
Noteworthy Insider Buying at This Biopharmaceutical Company and 2 Other Battered Companies
All major U.S indexes closed in the green on Friday, marking their fifth consecutive week of gains.
Hedge Fund Resource Center